Derek Gould
@Logos Global Management Lp
Latest period2024 - Q3ReportedManaged Assets$926.849MTotal holdings55
Assets growth rate-62.55%Assets growth rate (2-Q avg)18.89%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Logos Global Management Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 55 positions.
Assets under management
The assets under management (AUM) of Logos Global Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 926.849M in assets, with a quarterly growth rate of -62.55% and a 2-quarter average growth rate of 18.89%. The portfolio is managed by Derek Gould, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
ENGNEngene Holdings Inc
| 0.57% | $5.28M 800,000 shares@ $6.6 avg price | Decreased -66.66% |
AVTXAvalo Therapeutics Inc
| 0.56% | $5.121M 539,079 shares@ $9.51 avg price | |
LCTXLineage Cell Therapeutics In
| 0.49% | $4.526M 5M shares@ $0.91 avg price | Decreased -46.8% |
RAPPRapport Therapeutics Inc
| 0.44% | $4.065M 208,910 shares@ $19.46 avg price | |
SLNSilence Therapeutics Plc
| 0.4% | $3.636M 200,000 shares@ $18.18 avg price | Decreased -93.22% |
ATYRAtyr Pharma Inc
| 0.38% | $3.52M 2M shares@ $1.76 avg price | Decreased -66.66% |
NXTCNextcure Inc
| 0.37% | $3.425M 2.5M shares@ $1.37 avg price | Decreased -50% |
ADVMAdverum Biotechnologies Inc
| 0.32% | $2.925M 416,666 shares@ $7.02 avg price | Decreased -50% |
ARTVArtiva Biotherapeutics Inc
| 0.23% | $2.13M 145,089 shares@ $14.68 avg price | New Position |
UNCYUnicycive Therapeutics Inc
| 0.23% | $2.072M 5.079M shares@ $0.41 avg price | Decreased -26.81% |